Allaes Cardarine (GW 501516) 10 mg

Allaes Cardarine
Allaes Cardarine
NEW PRODUCT
Allaes Cardarine
Allaes Cardarine
Allaes Cardarine (GW 501516) 10 mg
  • Stock: In Stock
  • Package: 10 mg / 60 capsules
46.10€

Cardarine (GW-501516) — Fat Burning and Endurance Booster

What is Cardarine?

Cardarine (GW-501516) is an experimental compound often discussed for endurance support and fat-loss–related effects. It is frequently mentioned by athletes during cutting phases for perceived improvements in stamina, cardiovascular performance, and fat oxidation.

Mechanistically, Cardarine is described as a PPARδ receptor agonist, which may influence how the body uses fat for energy and how endurance adapts during prolonged activity.

How does Cardarine work?

Cardarine is associated with activation of the PPARδ receptor, which is linked to changes in fat metabolism and endurance-related pathways. Reported effects are commonly summarized as:

  1. Increased fat oxidation — supporting a shift toward using fat as fuel during activity.
  2. Leaner physique support — discussed for potential assistance with body-composition goals.
  3. Endurance and stamina — commonly cited for improved aerobic capacity and delayed fatigue.
  4. Cardiovascular markers — often discussed in the context of lipids (LDL/HDL, triglycerides).
  5. Inflammation pathways — sometimes reported in relation to vascular inflammation markers.

Who might consider discussing it with a clinician?

  • ✔ People aiming to improve endurance or body composition (as a discussion topic, not self-use).
  • ✔ Individuals with concerns about cardiovascular health who want evidence-based guidance.

Safety notes (important)

GW-501516 is not approved as a medication in many jurisdictions and is often sold as a research chemical. Self-administration can carry health and legal risks.

  • Potential adverse effects discussed include liver enzyme elevation, palpitations, headaches/dizziness, and fatigue.
  • If someone has used or is considering use, they should seek medical advice and consider lab monitoring (e.g., liver enzymes, lipids) under professional supervision.

If you use performance-enhancing substances

Many performance-enhancing drugs can negatively affect cardiovascular risk (for example, by worsening lipid profiles and blood pressure). The safest approach is to avoid unsupervised combinations and consult a licensed clinician for screening and monitoring.

Risk Warning for GW-501516

There is currently insufficient clinical data on the long-term effects of Cardarine (GW-501516) in humans, as it has not completed all necessary stages of clinical testing. However, animal studies suggest potential risks. In rodent experiments, prolonged use of high doses of Cardarine was associated with an increased risk of tumor formation in rats. As a result of these findings, the FDA halted all clinical trials of Cardarine in 2009.

That said, risk in humans cannot be directly inferred from animal data, as PPARδ receptors function differently in rodents and humans. The tumorigenic mechanisms observed in animals may be species-specific. Additionally, the doses typically used by humans are significantly lower — often 10 to 200 times less than those used in animal studies.

Despite the lack of direct human data, the medical community considers that using Cardarine — especially at higher-than-recommended doses — may pose a potential health risk. Some limited human studies using doses up to 10 mg/day for 12 weeks did not report tumor development.

While there is no conclusive evidence that Cardarine causes cancer in humans, it’s important to remember that safety data is lacking, and the animal research does point to possible risks.